Antibodies
21 September 2010
Roche provides results on Avastin in adjuvant colon cancer21 September 2010
ImmunoGen, Inc. Announces Start of SAR566658 Clinical Testing20 September 2010
Genentech Provides Update on Avastin for Advanced Breast Cancer20 September 2010
Epistem to Present Data from Their Model of Crohn’s Disease Colitis at the Inflammation Research Association Conference20 September 2010
Micromet Initiates Phase 2 Trial of Blinatumomab in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia20 September 2010
Ablynx Reports Positive Phase I Data for its Anti-Rankl Nanobody20 September 2010
Celldex Therapeutics Announces Initiation of Randomized Phase 2b Clinical Trial of CDX-011 in Advanced Breast Cancer16 September 2010
GlaxoSmithKline and Genmab Refocus Development Program for Ofatumumab in Autoimmune Indications14 September 2010
Genmab and Seattle Genetics Enter into Antibody-Drug Conjugate Research Collaboration14 September 2010
Biotie completes Phase I with VAP-1 antibody – BTT-1023 continues to demonstrate favourable safety profile13 September 2010
Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary Endpoint13 September 2010
Excelimmune Presents Preclinical Data at ICAAC Demonstrating that Human Recombinant Polyclonal Antibody Therapy Provides Protection Against MRSA13 September 2010
Progenics’ Humanized Monoclonal Antibodies Significantly Improve Survival in an Animal Model of C. difficile-associated Disease8 September 2010
New Octapharma 10% High Purity Immunoglobulin Enters Phase II/III Study in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)8 September 2010
Emergent BioSolutions Announces Commencement of Phase I Clinical Trial for Monoclonal Antibody to Treat Inhalational Anthrax8 September 2010
Anti-Angiogenic Anti-Cancer Agent Avastin Condition for Approval (All Patients Surveillance) Removed in Japan8 September 2010
PROLIA(TM) (denosumab) APPROVED BY HEALTH CANADA FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE8 September 2010
GSK and Genmab Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin’s Lymphoma2 September 2010
Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of AstellasNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports